Navigation Links
Third-party blood stem cell transplantation as a factor to impact on poor graft function
Date:3/18/2013

Putnam Valley, NY. (March 18, 2013) When a research team in China evaluated the efficacy and safety of using mesenchymal stem cells (MSCs) expanded from the bone marrow of non-self-donors to treat patients experiencing poor graft function (PGF) after receiving transplants of non-self-donated blood stem cells (allo-HSCT), they found that the mesenchymal stem cells were both safe and effective for treating primary and secondary PGF.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0832liu.

"Allogenic hematopoietic stem cell transplantation can cure many hematologic diseases," said study co-author Dr. Qifa Liu of the Southern Medical University in Guangzhou, China. "However, poor graft function is a complication that occurs in five to 27 percent of patients receiving allo-HSCT and is associated with considerable morbidity and mortality."

According to the researchers, graft function may be poor after allogenic hematopoietic stem cell transplantation because of slow or incomplete reconstitution of blood counts or decreasing blood counts. PGF, which is poorly understood, is a potentially life-threating condition when it leads to graft vs. host disease (GVHD).

In this study, when 20 patients demonstrated risk factors for PGF, researchers infused them with MSCs derived from bone marrow from third-party donors. PGF had developed in five patients with acute GVHD and two patients had chronic GVHD.

"The patients receiving the MSCs achieved either complete responses or improved GVHD," said the researchers. "However, the PGF did not improve when immunosuppressive agents were given. This means that additional studies will be needed to determine whether PGF is associated with immunologic factors."

One unanswered question, said the researchers, was whether the immunosuppressive properties of MSCs are an important factor that could have a favorable impact on potential problems such as an increased risk of infection or tumor relapse following cell transplantation.

"Although six of 20 patients died from infections within the first 100 days of MSC transplantation, we could not safely conclude that MSCs increased the incidence of infections other than Epstein-Barr," they wrote.

In conclusion, the researchers noted that "clinical applications of human MSCs are evolving rapidly with goals of improving hematopoietic engraftment and preventing GVHD after allogenic hematopoietic stem cell transplantation."

"This study highlights the potential impact of allogeneic mesenchymal stem cell transplants as an adjunctive therapy for hematopoietic stem cell transplantation to reduce the likelihood of the patient developing graft versus host disease after exhibiting risk factors for poor functioning of the grafted cells" said Dr. Paul R. Sanberg, distinguished professor at the Center of Excellence for Aging and Brain Repair, University of South Florida.
'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. White blood cells found to play key role in controlling red blood cell levels
2. Prenatal exposure to pesticide DDT linked to adult high blood pressure
3. Temp-controlled nanopores may allow detailed blood analysis
4. Omega-3s from fish vs. fish oil pills better at maintaining blood pressure in mouse model
5. Stressed proteins can cause blood clots for hours
6. Study uncovers enzymes double life, critical role in cancer blood supply
7. Manchester patients take part in pioneering heart attack blood test trial
8. Blood vessels sniff gut microbes to regulate blood pressure
9. Childhood blood lead levels rise and fall with exposure to airborne dust in urban areas
10. Blood is thicker than water -- and blood plasma is, too
11. Rice University lab show how blood vessels regroup after stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by ... Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region - ... grow from USD 10.74 Billion in 2015 to reach USD 32.73 Billion ... Continue Reading ... ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 2016 /PRNewswire/ -  Equicare Health Inc ., the leading ... as one of the top 100 companies in the ... that distinguishes the top digital health companies across the ... forward this year continually upgrading our product with the ... and team," says Len Grenier , CEO of ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
(Date:11/30/2016)... GREENWICH, Connecticut , November 30, 2016 ...   ... Aptuit, LLC today announced ... screening library. An additional 150,000 novel compounds have increased the ... selected to broaden the hit discovery capabilities of the company. ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... SSCI, the ... to discuss the implications of the latest FDA guidance on pharmaceutical cocrystals as ... 2016 in Cambridge, MA. , The event follows the successful November 15th ...
Breaking Biology Technology: